The effect of sorbinil, an aldose reductase inhibitor, on aortic function in control and streptozotocin-induced diabetic rats

Journal of Autonomic Pharmacology

Volumn 20, Issue 1, 2000, Pages 15-22

  Sellers, D J ^a   Chess Williams, R ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; CARBACHOL; FORSKOLIN; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; PONALRESTAT; SORBINIL;

ANIMAL MODEL; AORTA; ARTICLE; BODY WEIGHT; CARDIOVASCULAR EFFECT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MODEL; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ALDEHYDE REDUCTASE; ANIMAL; AORTA; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; DRUG INTERACTIONS; ENZYME INHIBITORS; IMIDAZOLES; MALE; RATS; RATS, WISTAR; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 0033778502     PISSN: 01441795     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2680.2000.00155.x     Document Type: Article

References (50)

1. Effects of a novel potent aldose reductase inhibitor. P-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats
2. Diabetes-induced changes in cardiac β-adrenoceptor responsiveness: Effects of aldose reductase inhibition with ponalrestat
3. Zopolrestat prevention of proteinuria, albuminuria and cataractogenesis in diabetes mellitus
4. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia Coli and autonomic function in patients with diabetes mellitus
5. Sorbitol in aortic endothelium of diabetic rats
6. Contractile properties of cardiac papillary muscle in streptozotocin-diabetic rats and the effects of aldose reductase inhibition
7. Impaired contraction and relaxation in aorta from streptozotocin-diabetic rats: Role of polyol pathway
8. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats
9. Iris vasculopathy in galactosefed rats
10. Endothelial dysfunction in diabetes mellitus
11. Effect of galactose and aldose reductase (AR) inhibition on renal hemodynamics
12. +-ATPase activity in acute and chronic diabetes and with aldose reductase inhibition
13. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats
14. Sorbinil suppresses glomerular prostaglandin production in the streptozotocin diabetic rat
15. Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years
16. Hyperglycaemia in the pathogenesis of diabetic complications
17. +/NADPH and alrestatin-like inhibitors
18. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs
19. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosemia in dogs
20. Kinetics of an orally absorbed aldose reductase inhibitor, sorbinil
21. The sorbinil pathway and the complications of diabetes
22. Amelioration of glomerular hyperfiltration in acute experimental diabetes mellitus by dietary myo-inositol supplementation and aldose reductase inhibition
23. Effects of aldose reductase inhibitors on the progression of nerve fiber damage in diabetic neuropathy
24. The effects of high glucose on polyol pathway activity and myoinositol metabolism in cultured endothelial cells
25. Le mecanisme de la transformation de glucose en fructose par les vesicules seminales
26. The fructose content of spinal fluid
27. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes-mellitus
28. Unchanged glomerular hyperfiltration following 3 months of aldose reductase inhibition with tolrestat in normoalbuminuric IDDM patients
29. Aldose reductase in diabetic complications of the eye
30. Cardiac sympathetic neuropathy and effects of aldose reductase inhibition in streptozotocin-induced diabetic rats
31. Immunohistochemical localization of aldose reductase II: Rat eye and kidney
32. Enzymic studies on TPN L-hexonate dehydrogenase from rat liver
33. Depression of contractile responses in rat aorta by spontaneously released endothelium-derived relaxing factor
34. Effects of sorbinil on glomerular structure and function in long-term-diabetic rats
35. The neutralization of hydroxyl radical by silibin, sorbinil and bendazac
36. Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent
37. Sorbinil prevents glomerular hyperperfusion in diabetic rats
38. Inhibition of human brain aldose reductase and hexonate dehydrogenase by alrestatin and sorbinil
39. Laevulose in the blood of the human foetus
40. The effects of aldose reductase inhibition with ponalrestat on changes in vascular function in streptozotocin diabetic rats
41. CP-45,634: A novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats
42. Comparison of aldose reductase inhibitors in vitro. Effects of enzyme purification and substrate type
43. Effect of the aldose reductase inhibitor tolrestat on nerve conduction velocity Na/K ATPase activity, and polyols in red blood cells, sciatic nerve, kidney cortex, and kidney medulla of diabetic rats
44. The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus
45. Sorbinil: A member of the novel class of spirohydantoin aldose reductase inhibitors
46. In-vitro assessment of a hypersensitivity syndrome associated with sorbinil
47. Endothelial function in the isolated perfused mesentery and aortae of rats with streptozotocin-induced diabetes: Effects of treatment with the aldose reductase inhibitor, ponalrestat
48. Aldose reductase and myoinositol in endothelial cell dysfunction caused by elevated glucose
49. Formation of polyols by the lens of the rat with 'sugar' cataract
50. The natural history of diabetic neuropathy: And the effect of tolrestat